유럽의 응고 시장 예측(-2030년) : 지역별 분석 - 증상별, 유형별, 제공별, 기술별, 최종사용자별

Europe Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Offering, Technology, and End User

US $ 3,450 ￦ 4,871,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450 ￦ 6,283,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450 ￦ 7,695,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

유럽의 응고 시장 규모는 2022년 20억 64만 달러로 평가되며, 2022-2030년 CAGR 6.8%로 성장하여 2030년에는 33억 7,971만 달러에 달할 것으로 예상됩니다.

심혈관 질환의 유병률 증가가 유럽 응고 시장을 주도

심장질환은 심방세동, 뇌졸중 등으로 인한 입원, 사망, 신체능력 저하의 주요 원인 중 하나입니다. 심장병은 지혈 시스템, 혈관 시스템, 혈액의 유체역학에 영향을 미쳐 동맥 및 정맥 혈전증을 유발합니다. 혈전증은 심혈관계 질환으로 인한 사망 및 합병증의 주요 원인입니다. 흡연과 고혈압으로 손상된 혈관은 혈관을 덮고 있는 콜레스테롤이 많은 플라크를 형성하고, 이 플라크가 파열되어 혈소판이 응고될 수 있습니다. 응고 장애는 심근경색, 뇌졸중, 혈관 층의 죽상동맥혈전성 사건의 위험을 초래할 수 있습니다. 심부전(HF)은 심방세동(AF) 유무와 관계없이 혈전색전증 위험 증가와 관련이 있습니다. 혈소판 활성화 및 응고계 이상은 심부전 환자에서 심각한 혈전색전증 위험을 증가시킵니다.

응고 검사는 심장마비를 일으킬 수 있는 혈액 응고를 예방하는 데 도움이 됩니다. 응고 분석기는 관상동맥 우회술이나 혈관 성형술 시 혈액 응고 상태에 대한 정보를 모니터링하는 데 사용됩니다. 이처럼 심혈관 질환의 발병률 증가는 응고 분석기 시장의 성장을 견인하고 있습니다.

유럽의 응고 시장 개요

유럽 응고 시장은 독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽으로 구분됩니다. 유럽은 세계 응고 시장에서 중요한 위치를 차지하고 있으며 2022-2030년 동안 견고한 CAGR을 기록할 것으로 추정됩니다. 이 지역의 시장 성장의 주요 요인은 심혈관 질환 발병률 증가, 의료기기 발전, 고령화 인구 증가, 응고 분석기 인지도 급증 등입니다.

독일에서는 많은 사람들이 심혈관 질환을 앓고 있으며, 이는 고령화 인구의 증가에 기인합니다. 심장마비는 관상동맥성 심장병(CHD)의 가장 심각한 결과입니다. 현재까지 독일 인구 중 360만 명 이상이 CHD 진단을 받았고, 130만 명 이상이 뇌졸중에서 살아남았으며, 2020년 발표된 WHO의 최신 데이터에 따르면 독일에서 CHD로 인한 사망자 수는 14만 7,055명(전체 사망자 수의 20.98%)에 달했습니다.

유럽 응고 시장 매출 및 2030년까지의 예측(금액)

유럽의 응고 시장 세분화

유럽 응고 시장은 증상, 유형, 제공, 기술, 최종사용자 및 국가별로 분류됩니다.

증상별로 유럽 응고 시장은 비타민 K 결핍, 간질환, 파종성 혈관 내 응고 및 폐색전증, 순환기 항응고제 개발, 혈우병, 폰빌레브란트병, 기타로 구분됩니다. 간질환 부문이 2022년 유럽 응고 시장 점유율을 가장 크게 차지했습니다.

유형별로 유럽 응고 시장은 임상 검사 분석기와 현장 검사 분석기로 구분되며, 2022년 유럽 응고 시장 점유율은 임상 검사 분석기 부문이 더 큰 비중을 차지했습니다. 임상 실험실 분석기 부문은 제어 및 교정기, 분석 및 시약, 기기/시스템, 응고인자, 기타로 세분화됩니다.

제품별로 유럽 응고 시장은 진단과 치료로 나뉩니다. 진단 부문은 2022년 유럽 응고 시장에서 더 큰 점유율을 차지했습니다. 진단 부문은 프로트롬빈 시간 검사, 피브리노겐 검사, 활성화 응고 시간 검사, 활성화 부분 트롬보플라스틴 시간 검사, d 다이머 검사, 혈소판 기능 검사 및 기타 활동으로 세분화됩니다. 치료 부문은 항선 용해제, 피임약, 데스모프레신 면역 억제제, 비타민 K 보충제, 혈액 희석제, 트롬빈 억제제 또는 혈전 용해제, 보충 요법, 카테터 보조 혈전제거 및 기타로 세분화됩니다.

기술별로 유럽 응고 시장은 광학 기술, 기계 기술, 전기 화학 기술, 기타로 구분되며, 2022년 유럽 응고 시장 점유율은 광학 기술 분야가 가장 컸습니다.

최종사용자별로 유럽 응고 시장은 임상 실험실, 병원, 기타로 구분됩니다. 병원 부문은 2022년 유럽 응고 시장에서 가장 큰 점유율을 차지했습니다.

국가별로 유럽 응고 시장은 독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽으로 분류되며, 2022년 독일이 유럽 응고 시장을 독점했습니다.

F. Hoffman-La Roche, Genrui Biotech, Horiba Manufacturing, ImproGen Diagnostik Kimya San. Ltd, Nordic Biomarker AB 등이 유럽 응고 시장에서 사업을 전개하고 있는 주요 기업들입니다.

목차

제1장 소개

제2장 주요 요약

• 주요 인사이트

제3장 조사 방법

• 조사 범위
• 2차 조사
• 1차 조사

제4장 유럽의 응고 시장 - 주요 산업 역학

• 주요 시장 성장 촉진요인
  • 혈액질환 유병률 증가
  • 심혈관질환 유병률 상승
• 시장 성장 억제요인
  • 응고 분석기 관련 고비용
• 시장 기회
  • 주요 시장 기업에 의한 유기적·무기적 전략 성장
• 향후 동향
  • POC(Point of Care) 응고 분석기 발전
• 영향 분석

제5장 응고 시장 : 유럽 시장 분석

• 유럽의 응고 시장 매출(2022-2030년)

제6장 유럽의 응고 시장 - 2030년까지 매출과 예측 : 증상별

• 유럽의 응고 시장 매출 점유율 : 증상별(2022년·2030년)
• 비타민 K 결핍증
• 간 질환
• 파종성 혈관내 응고 증후군과 폐색전증
• 순환형 항응고제 개발
• 혈우병
• 폰빌레브란트병
• 기타

제7장 유럽의 응고 시장 - 2030년까지 매출과 예측 : 유형별

• 유럽의 응고 시장 매출 점유율 : 유형별(2022년·2030년)
• 임상 검사 분석기
• POC(Point of Care) 검사 분석기

제8장 유럽의 응고 시장 - 2030년까지 매출과 예측 : 제공별

• 유럽의 응고 시장 매출 점유율 : 제공별(2022년·2030년)
• 진단
• 치료

제9장 유럽의 응고 시장 - 2030년까지 매출과 예측 : 기술별

• 유럽의 응고 시장 매출 점유율 : 기술별(2022년·2030년)
• 광학 기술
• 기계 기술
• 전기화학 기술
• 기타

제10장 유럽의 응고 시장 - 2030년까지 매출과 예측 : 최종사용자별

• 유럽의 응고 시장 매출 점유율 : 최종사용자별(2022년·2030년)
• 임상 검사실
• 병원
• 기타

제11장 유럽의 응고 시장 : 국가별 분석

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 기타 유럽

제12장 유럽의 응고 시장 - 업계 상황

• 응고 시장 성장 전략
• 무기적 성장 전략
• 유기적 성장 전략

제13장 기업 개요

• Siemens Healthineers AG
• ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti.
• Nordic Biomarker AB
• Sysmex Corp
• F. Hoffmann-La Roche Ltd
• Genrui Biotech Co., Ltd.
• Transasia Bio-Medicals Ltd
• Horiba Ltd.

제14장 부록

ksm

영문 목차

영문목차

The Europe coagulation market was valued at US$ 2,000.64 million in 2022 and is expected to reach US$ 3,379.71 million by 2030; it is estimated to grow at a CAGR of 6.8% from 2022 to 2030.

Rising Prevalence of Cardiovascular Diseases Fuel Europe Coagulation Market

Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.

A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.

Europe Coagulation Market Overview

The Europe coagulation market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe holds a significant position in the global coagulation market and is estimated to register a robust CAGR during 2022-2030. Market growth in this region is mainly attributed to the rising incidence of cardiovascular disorders, increasing advancements in medical devices, the growing aging population, and the surging awareness of coagulation analyzers.

A large number of people in Germany are suffering from cardiovascular disorders, which can be attributed to the growing aging population in the country. Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million of the German population have been diagnosed with CHD till date, and over 1.3 million have survived a stroke. According to the latest WHO data published in 2020, the count of deaths caused by CHD in Germany reached 147,055 (i.e., 20.98% of total deaths).

Europe Coagulation Market Revenue and Forecast to 2030 (US$ Million)

Europe Coagulation Market Segmentation

The Europe coagulation market is segmented based on disease indication, type, offering, technology, end user, and country.

Based on disease indication, the Europe coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held the largest Europe coagulation market share in 2022.

Based on type, the Europe coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held a larger Europe coagulation market share in 2022. Clinical laboratory analysers segment is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Europe coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held a larger Europe coagulation market share in 2022. Diagnosis segment is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment segment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Europe coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest Europe coagulation market share in 2022.

By end user, the Europe coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held the largest Europe coagulation market share in 2022.

Based on country, the Europe coagulation market is categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe coagulation market in 2022.

F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd.; Horiba Ltd; ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti.; Siemens Healthineers AG; Sysmex Corp; Transasia Bio-Medicals Ltd; and Nordic Biomarker AB are some of the leading companies operating in the Europe coagulation market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Coagulation Market - Key Industry Dynamics

• 4.1 Key Market Drivers:
  • 4.1.1 Increasing Prevalence of Blood Disorders
  • 4.1.2 Rising Prevalence of Cardiovascular Diseases
• 4.2 Market Restraints
  • 4.2.1 High Costs Associated with Coagulation Analyzers
• 4.3 Market Opportunities
  • 4.3.1 Growing Organic and Inorganic Strategies by Key Market Players
• 4.4 Future Trends
  • 4.4.1 Development of Point-of-Care (POC) Coagulation Analyzers
• 4.5 Impact Analysis

5. Coagulation Market - Europe Market Analysis

• 5.1 Europe Coagulation Market Revenue (US$ million), 2022 - 2030

6. Europe Coagulation Market - Revenue and Forecast to 2030 - by Disease Indication

• 6.1 Overview
• 6.2 Europe Coagulation Market Revenue Share, by Disease Indication 2022 & 2030 (%)
• 6.3 Vitamin K Deficiency
  • 6.3.1 Overview
  • 6.3.2 Vitamin K Deficiency: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Liver Disease
  • 6.4.1 Overview
  • 6.4.2 Liver Disease: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.5 Disseminated Intravascular Coagulation and Pulmonary Embolism
  • 6.5.1 Overview
  • 6.5.2 Disseminated Intravascular Coagulation and Pulmonary Embolism: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.6 Development of Circulating Anticoagulant
  • 6.6.1 Overview
  • 6.6.2 Development of Circulating Anticoagulant: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.7 Hemophilia
  • 6.7.1 Overview
  • 6.7.2 Hemophilia: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.8 Von Willebrand's Disease
  • 6.8.1 Overview
  • 6.8.2 Von Willebrand's Disease: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 6.9 Others
  • 6.9.1 Overview
  • 6.9.2 Others: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Coagulation Market - Revenue and Forecast to 2030 - by Type

• 7.1 Overview
• 7.2 Europe Coagulation Market Revenue Share, by Type 2022 & 2030 (%)
• 7.3 Clinical Laboratory Analyzers
  • 7.3.1 Overview
  • 7.3.2 Clinical Laboratory Analyzers: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.2.1 Europe Coagulation Market, by Clinical Laboratory Analyzers
• 7.4 Point-of-Care Testing Analyzers
  • 7.4.1 Overview
  • 7.4.2 Point-of-Care Testing Analyzers: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Coagulation Market - Revenue and Forecast to 2030 - by Offering

• 8.1 Overview
• 8.2 Europe Coagulation Market Revenue Share, by Offering 2022 & 2030 (%)
• 8.3 Diagnosis
  • 8.3.1 Overview
  • 8.3.2 Diagnosis: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.3.2.1 Europe Coagulation Market, by Diagnosis
• 8.4 Treatment
  • 8.4.1 Overview
  • 8.4.2 Treatment: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.4.2.1 Europe Coagulation Market, by Treatment

9. Europe Coagulation Market - Revenue and Forecast to 2030 - by Technology

• 9.1 Overview
• 9.2 Europe Coagulation Market Revenue Share, by Technology 2022 & 2030 (%)
• 9.3 Optical Technology
  • 9.3.1 Overview
  • 9.3.2 Optical Technology: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 9.4 Mechanical Technology
  • 9.4.1 Overview
  • 9.4.2 Mechanical Technology: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 9.5 Electrochemical Technology
  • 9.5.1 Overview
  • 9.5.2 Electrochemical Technology: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 9.6 Others
  • 9.6.1 Overview
  • 9.6.2 Others: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Coagulation Market - Revenue and Forecast to 2030 - by End User

• 10.1 Overview
• 10.2 Europe Coagulation Market Revenue Share, by End User 2022 & 2030 (%)
• 10.3 Clinical Laboratories
  • 10.3.1 Overview
  • 10.3.2 Clinical Laboratories: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 10.4 Hospitals
  • 10.4.1 Overview
  • 10.4.2 Hospitals: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)
• 10.5 Others
  • 10.5.1 Overview
  • 10.5.2 Others: Europe Coagulation Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Coagulation Market - Country Analysis

• 11.1 Europe Coagulation Market, Revenue and Forecast to 2030
  • 11.1.1 Europe Coagulation Market by Country
    • 11.1.1.1 Germany
      • 11.1.1.1.1 Overview
      • 11.1.1.1.2 Germany Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.1.3 Germany Coagulation Market, by Disease Indication
      • 11.1.1.1.4 Germany Coagulation Market, by Type
      • 11.1.1.1.4.1 Germany Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.1.5 Germany Coagulation Market, by Offering
      • 11.1.1.1.5.1 Germany Coagulation Market, by Diagnosis
      • 11.1.1.1.5.2 Germany Coagulation Market, by Treatment
      • 11.1.1.1.6 Germany Coagulation Market, by Technology
      • 11.1.1.1.7 Germany Coagulation Market, by End User
    • 11.1.1.2 UK
      • 11.1.1.2.1 Overview
      • 11.1.1.2.1.1 UK Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.2.2 UK Coagulation Market, by Disease Indication
      • 11.1.1.2.3 UK Coagulation Market, by Type
      • 11.1.1.2.3.1 UK Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.2.4 UK Coagulation Market, by Offering
      • 11.1.1.2.4.1 UK Coagulation Market, by Diagnosis
      • 11.1.1.2.4.2 UK Coagulation Market, by Treatment
      • 11.1.1.2.5 UK Coagulation Market, by Technology
      • 11.1.1.2.6 UK Coagulation Market, by End User
    • 11.1.1.3 France
      • 11.1.1.3.1 Overview
      • 11.1.1.3.1.1 France Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.3.2 France Coagulation Market, by Disease Indication
      • 11.1.1.3.3 France Coagulation Market, by Type
      • 11.1.1.3.3.1 France Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.3.4 France Coagulation Market, by Offering
      • 11.1.1.3.4.1 France Coagulation Market, by Diagnosis
      • 11.1.1.3.4.2 France Coagulation Market, by Treatment
      • 11.1.1.3.5 France Coagulation Market, by Technology
      • 11.1.1.3.6 France Coagulation Market, by End User
    • 11.1.1.4 Italy
      • 11.1.1.4.1 Overview
      • 11.1.1.4.1.1 Italy Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.4.2 Italy Coagulation Market, by Disease Indication
      • 11.1.1.4.3 Italy Coagulation Market, by Type
      • 11.1.1.4.3.1 Italy Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.4.4 Italy Coagulation Market, by Offering
      • 11.1.1.4.4.1 Italy Coagulation Market, by Diagnosis
      • 11.1.1.4.4.2 Italy Coagulation Market, by Treatment
      • 11.1.1.4.5 Italy Coagulation Market, by Technology
      • 11.1.1.4.6 Italy Coagulation Market, by End User
    • 11.1.1.5 Spain
      • 11.1.1.5.1 Overview
      • 11.1.1.5.2 Spain Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.5.3 Spain Coagulation Market, by Disease Indication
      • 11.1.1.5.4 Spain Coagulation Market, by Type
      • 11.1.1.5.4.1 Spain Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.5.5 Spain Coagulation Market, by Offering
      • 11.1.1.5.5.1 Spain Coagulation Market, by Diagnosis
      • 11.1.1.5.5.2 Spain Coagulation Market, by Treatment
      • 11.1.1.5.6 Spain Coagulation Market, by Technology
      • 11.1.1.5.7 Spain Coagulation Market, by End User
    • 11.1.1.6 Rest of Europe
      • 11.1.1.6.1 Overview
      • 11.1.1.6.2 Rest of Europe Coagulation Market Revenue and Forecast to 2030 (US$ million)
      • 11.1.1.6.3 Rest of Europe Coagulation Market, by Disease Indication
      • 11.1.1.6.4 Rest of Europe Coagulation Market, by Type
      • 11.1.1.6.4.1 Rest of Europe Coagulation Market, by Clinical Laboratory Analyzers
      • 11.1.1.6.5 Rest of Europe Coagulation Market, by Offering
      • 11.1.1.6.5.1 Rest of Europe Coagulation Market, by Diagnosis
      • 11.1.1.6.5.2 Rest of Europe Coagulation Market, by Treatment
      • 11.1.1.6.6 Rest of Europe Coagulation Market, by Technology
      • 11.1.1.6.7 Rest of Europe Coagulation Market, by End User

12. Europe Coagulation Market-Industry Landscape

• 12.1 Overview
• 12.2 Growth Strategies in the Coagulation Market
• 12.3 Inorganic Growth Strategies
  • 12.3.1 Overview
• 12.4 Organic Growth Strategies
  • 12.4.1 Overview

13. Company Profiles

• 13.1 Siemens Healthineers AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 ImproGen Diagnostik Kimya San. & Tic. Ltd.Sti.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Nordic Biomarker AB
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 Sysmex Corp
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 F. Hoffmann-La Roche Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 Genrui Biotech Co., Ltd.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
• 13.7 Transasia Bio-Medicals Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 Horiba Ltd.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

• 14.1 About Us
• 14.2 Glossary of Terms

관련자료